Sunlenca (Lenacapavir)

unlenca (lenacapavir) is an injectable treatment used in combination with other HIV-1 medicines for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) individuals with multidrug-resistant (MDR) HIV-1 infection failing their current antiretroviral regimen due to intolerance, resistance, or safety considerations.

Recommended Dosage: Sunlenca is supplied as oral tablets and a subcutaneous (SC) injection. Therapy is started using a dosing regimen that consists of both injections and tablets. Maintenance therapy consists of injections administered every 6 months. Treatment can be started using 1 of 2 recommended dosage regimens. Clinicians should determine the apt initiation regimen for the patient. Sunlenca tablets may be taken with or without food.

• Initiation Option 1: On treatment Day 1, the recommended dose of Sunlenca is 927 mg administered by subcutaneous injection (2 × 1.5 mL injections) and 600 mg orally (2 × 300 mg tablets). On treatment Day 2, the recommended dose of Sunlenca is 600 mg orally (2 × 300 mg tablets).
  
• Initiation Option 2: On treatment Day 1 and Day 2, the recommended dose of Sunlenca is 600 mg (2 × 300 mg tablets) per day taken orally. On treatment Day 8, the recommended dose is 300 mg taken orally. Then, on treatment Day 15, the recommended dose is 927 mg administered by subcutaneous injection (2 × 1.5 mL injections).
  
• Maintenance: The recommended dose of Sunlenca is 927 mg administered by subcutaneous injection (2 × 1.5 mL injections) once every 6 months (26 weeks) from the date of the final/last injection (+/- 2 weeks).  

• Immune reconstitution syndrome may occur in patients treated with combination antiretroviral treatment. Throughout the initial phase of combination antiretroviral therapy, individuals whose immune system responds may establish an inflammatory response to indolent or residual opportunistic infections.
  
• Certain autoimmune disorders (such as Guillain-Barré syndrome, Graves’ disease, polymyositis, and autoimmune hepatitis) may occur in the setting of immune reconstitution; however, the time to onset is more variable and can establish many months following initiation of treatment.  
  
• Residual concentrations of this medicine (lenacapavir) may remain in the systemic circulation of patients for prolonged periods (up to 1 year or longer after the final subcutaneous (SC) dose). It is crucial to counsel patients that maintenance dosing by injection is needed every six months.
  
• The use of Lenacapavir may cause local injection site reactions (ISRs). If clinically significant ISRs occur, assess and institute suitable treatment and follow-up. Manifestations of injection site reactions may include erythema, swelling, pain, pruritus, nodule, induration, extravasation, or mass.
  

Indian Pharma Network is able to source the SUNLENCA (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Sunlenca®?

Lenacapavir is a Generic Name for the trade name drug Sunlenca®.

What is the Manufacturer’s Name of Sunlenca®?

Sunlenca® is manufactured by Gilead Sciences, Inc.

Where can I get Sunlenca® at the best price in India?

To get the best Sunlenca price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Sunlenca®, a valid medical prescription is required from a treating physician.

Is Sunlenca® approved by the FDA?

Yes, Sunlenca® is approved by the FDA. Date of first approval: December 22, 2022.

What is the dosage and form of Sunlenca® supplied?

Sunlenca® is supplied as Tablets: 300 mg (for oral administration) and Injection: 463.5 mg/1.5 mL (309 mg/mL) in single-dose vials (for subcutaneous use). 

What are the most common side effects of Sunlenca®? 

The most commonly reported side effects of Sunlenca® are injection site reactions and nausea. 

How much does Sunlenca® cost in India?

The cost of Sunlenca in India can vary. In order to procure this HIV-1 capsid inhibitor legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Sunlenca®?

Store at 20 °C to 25 °C (68 °F to 77 °F), excursions permitted to 15 °C to 30 °C (59 °F to 86 °F). 

Is it safe to buy Sunlenca® online in India?

Yes, one can buy Sunlenca online in India at the lowest price from the Indian Pharma Network (IPN) if it is not (yet) registered or available in their country. We can help facilitate the supply of Sunlenca® through legal channels.